Regulation of dendropoiesis in cancer

Clinical Immunology Newsletter

Volumn 19, Issue 10-11, 1999, Pages 135-139

  Shurin, Michael R ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN PRESENTATION; CANCER GROWTH; CELL PROLIFERATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GROWTH REGULATION; HOST RESISTANCE; HUMAN; IMMUNOSTIMULATION; NATURAL KILLER CELL; REVIEW; SIGNAL TRANSDUCTION;

EID: 0033208388     PISSN: 01971859     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-1859(00)87088-0     Document Type: Note

References (40)

1. Wojtowicz-Praga S: Reversal of tumor-induced immunosuppression: A new approach to cancer therapy (see comments). J Immunother20:165-177, 1997.
2. Esche C, Lokshin A, Shurin GV, Gastman BR, RabinowicH H, Watkins SC, Lotze MT, Shurin MR: Tumor's other immune targets: Dendritic cells (In Process Citation). J Leukoc Biol 66:336-344, 1999.
3. Shurin MR: Dendritic cells presenting tumor antigen. Cancer Immunol Immunother 43:158-64, 1996.
4. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 392:245-252, 1998.
5. Steinman RM, Inaba K: Myeloid dendritic cells. J Leukoc Biol 66:205-208, 1999.
6. Olweus J, BitMansour A, Warnke R, Thompson PA, Carballido J, Picker LJ, Lund-Johansen F: Dendritic cell ontogeny: A human dendritic cell lineage of myeloid origin. Proc Natl Acad Sci USA 94:12551-12556, 1997.
7. Shortman K, Vremec D, Corcoran LM, Georgopoulos K, Lucas K, Wu L: The linkage between T-cells and dendritic cell development in mouse thymus. Immunol Rev 165:39-46, 1998.
8. Flamand V, Sornasse T, Thielemans K, Demanet C, Bakkus M, Bazin H, Tielemans F, Leo O, Urbain JMM: Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol 24:605-610, 1994.
9. Mayordomo JI, Zorina T, Storkus WJ, Celluzzi C, Falo LD, Melief CJ, Ildstad T, Kast WM, DeLeo AB, Lotze MT: Bone-marrow derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1:1297-1302, 1995.
10. Gilboa E, Nair SK, Lyerly HK: Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol Immunother 46:82-87, 1998.
11. Lyman SD, Jacobsen SE: C-kit ligand and Flt3 ligand: Stem/progenitor cell factors with overlapping yet distinct activities. Blood 91:1101-1134, 1998.
12. Maraskovsky E, Brasel K, Teepe M, Roux ER, Lyman SD, Shortman K, McKenna HJ: Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: Multiple dendritic cell subpopulations identified. J Exp Med 184:1953-1962, 1996.
13. Shurin MR, Pandharipande PP, Zorina TD, Haluszczak C, Subbotin VM, Hunter O, Brumfield A, Storkus WJ, Maraskovsky E, Lotze MT: FLT3 ligand induces the generation of functionally active dendritic cells in mice. Cell Immunol 179:174-184, 1997.
14. Lynch D, Andreasen A, Maraskovsky E, Whitmore J, Miller R, Schuh J: Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat Med 3:625-631, 1997.
15. Esche C, Subbotin V, Maliszewski C, Lotze M, Shurin M: FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma. Cancer Res 58:380-383, 1998.
16. Peron J, Esche C, Subbotin V, Maliszewski C, Lotze M, Shurin M: FLT3-ligand administration inhibits liver metastases-role of NK cells. J Immunol 161:6164-6170, 1998.
17. McKenna HJ: Generating a T-cell tumor-specific immune response in vivo: Can flt3- Ligand-generated dendritic cells tip the balance? Cancer Immunol Immunother 48:281-286, 1999.
18. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D, Carbone DP: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells (published erratum appears in Nat Med 2:1267, 1996), Nat Med 2:1096-103, 1996.
19. Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, Carbone DP: Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92:4150-4166, 1998.
20. Oyama T, Ran S, Ishida T, Nadaf S, Kerr L, Carbone D, Gabrilovich DI: Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-κB activation in hematopoietic progenitor cells. J Immunol 160:1224-1232, 1998.
21. Ohm JE, Shurin MR, Esche C, Lotze MT, Carbone DP, Gabrilovich DI: Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo (In Process Citation). J Immunol 163:3260-3208, 1999.
22. +) progenitors by tumor cells: Role of interleukin-6 and macrophage-colony-stimuating factor. Blood 92:4778-4791, 1998.
23. + progenitor cells. Med Oncol 16:46-52, 1999.
24. Yamaguchi Y: Developmental regulation by cytokines of bone marrow-derived dendritic cells and epidermal langerhans cells. Microbiol Immunol 42:639-650, 1998.
25. Yamaguchi Y: Regulation of GM-CSF-induced dendritic cell development by TGF-beta1 and co-developing macrophages. Microbiol Immunol 42:627-637, 1998.
26. Blanckaert VD, Schelling ME, Elstad CA, Meadows GG: Differential growth factor production, secretion, and response by high and low metastatic variants of B16BL6 melanoma. Cancer Res 53:4075-4081, 1993.
27. Arteaga CL, Carty-Dugger T, Moses HL, Hurd SD, Pietenpol JA: Transforming growth factor beta 1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice. Cell Growth Differ 4:193-201, 1993.
28. Lattime EC, Mastrangelo MJ, Bagasra O, Li W, Berd D: Expression of cytokine mRNA in human melanoma tissues. Cancer Immunol Immunother 41:151-156, 1995.
29. Nakagomi H, Pisa P, Pisa E, Yamamoto Y, Halapi E, Backlin K, Juhlin C, Kiessling R: Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma. Intern J Cancer 63:366-371, 1995.
30. Young MR, Wheeler E, Newby M: Macrophage-mediated suppression of natural killer cell activity in mice bearing Lewis lung carcinoma. J Natl Cancer Inst 76:745-750, 1986.
31. McLemore TL, Hubbard WC, Litterst CL, Liu MC, Miller S, McMahon NA, Eggleston JC, Boyd MR: Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. Cancer Res 48:3140-3147, 1988.
32. Lopez DM, Lopez-Cepero M, Watson GA, Ganju A, Sotomayor E, Fu YX: Modulation of the immune system by mammary tumor-derived factors. Cancer Invest 9:643-653, 1991.
33. Nikcevich DA, Young MR, Ellis NK, Newby M, Wepsic HT: Stimulation of hematopoiesis in untreated and cyclophosphamide treated mice by the inhibition of prostaglandin synthesis. J Immunopharmacol 8:299-313, 1986.
34. Pelus LM, Gentile PS: In vivo modulation of myelopoiesis by prostaglandin E2. III. Induction of suppressor cells in marrow and spleen capable of mediating inhibition of CFU-GM proliferation. Blood 71:1633-1640, 1988.
35. + dendritic cells. Immunol 86:15, 1995.
36. + dendritic cells: The levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. J Immunol 161:2804-2809, 1998.
37. Kambayashi T, Alexander HR, Fong M, Strassmann G: Potential involvement of IL-10 in suppressing tumor-associated macrophages. Colon-26-derived prostaglandin E2 inhibits TNF-alpha release via a mechanism involving IL-10. J Immunol 154:3383-3390, 1995.
38. Huang M, Sharma S, Mao JT, Dubinett SM: Non-small cell lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein production. J Immunol 157:5512-5520, 1996.
39. van Den Heuvel MM, van Beek NM, Broug-Holub E, Postmus PE, Hoefsmit EC, Beelen RH, Kraal G: Glucocorticoids modulate the development of dendritic cells from blood precursors. Clin Exp Immunol 115:577-583, 1999.
40. Vieira PL, Kalinski P, Wierenga EA, Kapsenberg ML, de Jong EC: Glucocorticoids inhibit bioactive IL-12p70 production by in vitro-generated human dendritic cells without affecting their T-cell stimulatory potential. J Immunol 161:5245-5251, 1998.